GoingToMeet

Recent advances in targeted therapy have unequivocally demonstrated the activity of these compounds in cancer patients. Following on the clinical successes of imitanib and trastuzamab, pharmaceutical companies have filled their oncology pipelines with small molecule kinase inhibitors. Work on identifying the most active agents for specific tumor types and increasing efficacy with combination targeted therapy has become the primary focus of translational oncology research. However, this field is in its infancy, with much to be learned about which molecules to target, how to go beyond kinase inhibitors, how to optimize dose and scheduling of these new classes of drugs and how to tailor therapy to the genetic architecture of individual tumors. This conference will bring together experts in the key disciplines of cell biology, biochemistry, molecular genetics, medicinal chemistry, imaging and clinical oncology to identify critical problems that may best be addressed using a multidisciplinary approach and foster those collaborations.